Sagimet Biosciences Inc. gets a Buy rating as denifanstat targets MASH & acne; key Phase 3 catalysts and funding risks ahead.

Alexander, a traveler from Stavropol Krai who was known online by the name “Sasha Kon,” was killed on May 13 in Russia’s ...

Decorated Russian actress Olga Vasilieva has dismissed as a fake a claim that she had petitioned the State Duma to allow her ...

Welcome to Widow’s Bay, which feels a lot like somewhere you’ve never been before. The point of listing all these references ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious ...

Experts are cautioning that Jamaica may be moving too quickly to reopen the bird shooting season following Hurricane Melissa, ...

Sixth-seeded Florida, home again for NCAA Tournament regional play, begins its 2026 quest for a return trip to Oklahoma City ...

WALKERS has revealed three brand new crisp flavours set to hit supermarket shelves ahead of the World Cup. This summer is set ...

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in 'Best of EASL 2026” by EASL ...

Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET ...

Q1 2026 Management View "In April, we completed an oversubscribed public offering resulting in $225 million in gross proceeds" and "the proceeds from the April offering, along with our existing funds, ...

Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today ...